Aldeyra Therapeutics (ALDX): AQR Capital Management, LLC cut its ALDX stake below 5% (1.1%) 1.1%

1.1%

Stake

673K

Shares owned

Stake as of

Sep 30, 2026

Filed

Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

What came next

1. Nov 6, 20265% stakeBarclays PLC reported a passive stake (13G) of 5.5%
2. Nov 11, 2026Insider · 2 peopleInsiders: 2 purchases (~$135K)
3. Nov 12, 20265% stakeAQR Capital Management, LLC reported a passive stake (13G) of 1.1%

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Aldeyra Therapeutics

For Aldeyra Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALDX page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Aldeyra Therapeutics

• SEC Form 4Nov 13, 2026
• SEC Form 4Nov 13, 2026
• SEC Schedule 13GNov 6, 2026
• SEC Form 4Jun 5, 2026
• SEC Form 13F-HRMay 29, 2026
• SEC Form 4Mar 20, 2026

Everything OQRO holds on this company is on its ALDX page.